How tumors escape immune destruction and what we can do about it

Cancer Immunology Immunotherapy

Volumn 48, Issue 7, 1999, Pages 382-385

  Gilboa, Eli ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer immunotherapy; Immune escape; Tumors

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CANCER CONTROL; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CYTOKINE PRODUCTION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ESCAPE; TUMOR GROWTH; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; DOWN-REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE TOLERANCE; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

EID: 0032843881     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050590     Document Type: Conference Paper

References (28)

1. Anichini A, Mortarini R, Maccalli C, et al (1996) Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 156:208
2. Bicknell DC, Rowan A, Bodmer WF (1994) β2-Microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci U S A 91:4751
3. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are patent antigen-presenting cells in vitro in viva. J Exp Med 184:465
4. Bodmer S, Strommer K, Frei K et al (1989) Immunosuppression and transforming growth factor-β in glioblastoma. J Immunol 143:3222
5. Borrow P, Shaw GM (1998) Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in viva? Immunol Rev 164:37
6. Chen HL, Gabrilovich D, Virmani A et al (1996) Structural and functional analysis of β2 microglobulin abnormalities in human lung and breast cancer. Int J Cancer 67:756
7. Cormier JN, Hijazi YM, Abati A et al (1998) Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in viva. Int J Cancer 75:517
8. De Giovanni G, Lahaye T, Herin M, Hainaut P, Boon T (1988) Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones. Eur J Immunol 18:671
9. Ferrone S, Marincola FM (1995) Loss of HLA class 1 antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487
10. Garrido F, Ruiz-Cabello F, Cabrera T et al (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89
11. Gilboa E, Nair SK, Lyerly HK (1998) Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 46:82
12. Guerder S, Matzinger P (1992) A fail-safe mechanism for maintaining self-tolerance. J Exp Med 176:553
13. Hermans IF, Daish A, Yang J, Ritchie DS, Ronchese F (1998) Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res 58:3909
14. Hicklin DJ, Marincola FM, Ferrone S (1999) HLA class I antigen downregulation in human cancers - assembling the story. Mol Med Today (in press)
15. Lee K-H, Panelli MC, Kim CJ et al (1998) Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 161:4183
16. Lehmann F, Marchand M, Hainaut P et al (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340
17. Maeurer MJ, Gollin SM, Martin D et al (1996) Tumor escape from immune recognition. J Clin Invest 98:1633
18. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991
19. Nair S, Boczkowski D, Snyder D, Rouse BT, Gilboa E (1997) Regression of tumors in mice vaccinated with professional antigen presenting cells pulsed with tumor extracts. Int J Cancer 70:706
20. Natali PG, Giacomini P, Bigotti A et al (1983) Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res 43:660
21. Porgador A, Feldman M, Eisenbach L (1989) H-2 Kb transfection of B16 melanoma cells results in reduced tumorigenicity and metastatic competence. J Immunogenet 16:291
22. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA (1996) Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100
23. Rosenberg SA, Kawakami Y, Robbins PF, Wang R (1996) Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res 70:145
24. Seliger B, Maeurer MJ, Ferrone S (1997) TAP off - tumors on. Immunol Today 18:292
25. Speiser DE, Miranda R, Zakarian A et al (1997) Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186:645
26. Srivastava PK (1996) Do human cancers express shared protective antigens? or The necessity of remembrance of things past. Immunology 8:295
27. Staveley-O'Carroll K, Sotomayor E, Montgomery J et al (1998) Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 95:1178
28. Zajac AJ, Murali-Krishna K, Blattman JN, Ahmed R (1998) Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4 + and CD8 + T cells. Curr Opin Immunol 10:444